Alemtuzumab: Evidence for its potential in relapsing-remitting multiple sclerosis

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 131-138

  Brown, J William L ^a   Coles, Alasdair J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Alemtuzumab; Campath; Efficacy; Relapsing remitting multiple sclerosis

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; BETA1A INTERFERON; GADOLINIUM; METHYLPREDNISOLONE; NATALIZUMAB; PLACEBO;

AUTOIMMUNE CYTOPENIA; AUTOIMMUNE DISEASE; AUTOIMMUNE SKIN DISEASE; AUTOIMMUNITY; BRAIN ATROPHY; BRAIN DAMAGE; BRAIN HEMORRHAGE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CHRONIC LYMPHATIC LEUKEMIA; CONTRAST ENHANCEMENT; CYTOKINE RELEASE SYNDROME; CYTOPENIA; DEEP VEIN THROMBOSIS; DISEASE DURATION; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; EUROPE; EVIDENCE BASED MEDICINE; EXPANDED DISABILITY STATUS SCALE; GOITER; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION; INFUSION RELATED REACTION; LUNG EMBOLISM; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT MONITORING; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; RHEUMATOID ARTHRITIS; RISK REDUCTION; SYSTEMIC VASCULITIS; THYROID DISEASE; THYROIDITIS; TREATMENT DURATION; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UTERINE CERVIX CARCINOMA IN SITU; UVEITIS;

ALEMTUZUMAB; CAMPATH; EFFICACY; RELAPSING-REMITTING MULTIPLE SCLEROSIS;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD; ANTIGENS, NEOPLASM; GLYCOPROTEINS; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TREATMENT OUTCOME;

EID: 84874920634     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S32687     Document Type: Review

References (33)

1. Trisolini M, Honeycutt A, Wiener J, Lesesne S; for Multiple Sclerosis International Federation. Global Economic Impact of Multiple Sclerosis. London: Multiple Sclerosis International Federation; 2010.
2. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648): 1502-1517.
3. Disanto G, Morahan JM, Barnett MH, Giovannoni G, Ramagopalan SV. The evidence for a role of B cells in multiple sclerosis. Neurology. 2012;78(11):823-832.
4. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology. 1995;45(7):1277-1285.
5. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998;352(9139):1498-1504.
6. Jacobs LD, Cookfair DL, Rudick RA, etal. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39(3):285-294.
7. Johnson KP, Brooks BR, Cohen JA, etal. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45(7):1268-1276.
8. Polman CH, O'Connor PW, Havrdova E, etal; for AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.
9. Rudick RA, Stuart WH, Calabresi PA, etal; for SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911-923.
10. Cohen JA, Barkhof F, Comi G, etal; for TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402-415.
11. Kappos L, Radue EW, O'Connor P, etal; for FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401.
12. Schnitzer TJ, Yocum DE, Michalska M, etal. Subcutaneous administration of CAMPATH-1H: clinical and biological outcomes. J Rheumatol. 1997;24(6):1031-1036.
13. Lockwood CM, Thiru S, Isaacs JD, Hale G, Waldmann H. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet. 1993;341(8861):1620-1622.
14. Lockwood CM, Thiru S, Stewart S, etal. Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. QJM. 1996;89(12):903-912.
15. Lim SH, Hale G, Marcus RE, Waldmann H, Baglin TP. CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura. Br J Haematol. 1993;84(3):542-544.
16. Marsh EA, Hirst CL, Llewelyn JG, etal. Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. J Neurol. 2010;257(6):913-919.
17. Isaacs JD, Hale G, Waldmann H, etal. Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H. Br J Ophthalmol. 1995;79(11):1054-1055.
18. Zhou J, Ju WQ, He XS, etal. Effect of Campath-1H induction on immunosuppression in small intestine transplantation. Zhonghua Wei Chang Wai Ke Za Zhi. 2011;14(3):199-201. Chinese.
19. Barth RN, Janus CA, Lillesand CA, etal. Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. Transpl Int. 2006;19(11):885-892.
20. Hill-Cawthorne GA, Button T, Tuohy O, etal. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012;83(3):298-304.
21. Cox AL, Thompson SA, Jones JL, etal. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol. 2005;35(11):3332-3342.
22. Cohen JA, Coles AJ, Arnold DL, etal; for CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1819-1828.
23. Coles AJ, Compston DA, Selmaj KW, etal; for CAMMS223 Investigators. Alemtuzumab vs interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786-1801.
24. Coles AJ, Cox A, Le Page E, etal. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol. 2006;253(1):98-108.
25. Coles AJ, Twyman CL, Arnold DL, etal; for CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1829-1839.
26. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-1452.
27. Hirst CL, Pace A, Pickersgill TP, etal. Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. J Neurol. 2008;255(2):231-238.
28. Fox EJ, Sullivan HC, Gazda SK, etal. A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis. Eur J Neurol. 2012;19(2):307-311.
29. Coles AJ, Fox E, Vladic A, etal. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology. 2012;78(14):1069-1078.
30. Thompson SA, Jones JL, Cox AL, Compston DA, Coles AJ. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol. 2010;30(1):99-105.
31. Coles AJ, Fox E, Vladic A, etal. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol. 2011;10(4):338-348.
32. Costelloe L, Jones J, Coles A. Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis. Expert Rev Neurother. 2012;12(3):335-341.
33. Jones JL, Phuah CL, Cox AL, etal. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest. 2009;119(7):2052-2061.